8-K
filed August 10, 2023, 7:59 PM ET
ticker NDRA
CIK 0001681682
other
confidence high
sentiment neutral
materiality 0.10
ENDRA Life Sciences annual meeting elects directors, approves say-on-pay frequency of 1 year
ENDRA Life Sciences Inc.
- All five director nominees elected: Michelon (2,024,988 for), Basenese (1,628,081), DiGiandomenico (1,976,138), Harsh (1,958,901), Tokman (2,054,532).
- Say-on-pay approved with 80% of votes cast in favor (1,733,406 for, 340,392 against, 71,792 abstain).
- Stockholders recommend say-on-pay every 1 year (1,743,563 votes); board adopts annual frequency until next required vote in 6 years.
- RBSM LLP ratified as independent auditor for FY2023 with 94% of votes for (2,794,638 for, 126,032 against, 63,296 abstain).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENDRA Life Sciences Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-08-09 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-08-09
Exact text from the filing
Proposal 3 – The Company’s stockholders recommended, on an advisory basis, holding advisory votes on the compensation paid to the Company’s named executive officers every year: One Year Two Years Three Years Abstain Broker Non-Votes 1,743,563 111,671 241,373 48,983 838,376
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENDRA Life Sciences Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-08-09 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-08-09
Exact text from the filing
Proposal 2 – The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers: For Against Abstain Broker Non-Votes 1,733,406 340,392 71,792 838,376
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENDRA Life Sciences Inc. shareholders approved Election of five directors to serve until the next annual meeting at the 2023-08-09 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-08-09
Exact text from the filing
The certified results of the matters voted upon at the meeting, which are more fully described in the Proxy Statement for the Annual Meeting as filed with the Securities and Exchange Commission on May 24, 2023 (the “Proxy Statement”), are as follows: Proposal 1 – The Company’s stockholders elected the five directors nominated by the Company’s Board of Directors to serve until the next annual meeting of stockholders and the election of their successors: For Withheld Broker Non-Votes Francois Michelon 2,024,988 120,602 838,376 Louis J. Basenese 1,628,081 517,509 838,376 Anthony DiGiandomenico 1,976,138 169,452 838,376 Michael Harsh 1,958,901 186,689 838,376 Alexander Tokman 2,054,532 91,058 838,376
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENDRA Life Sciences Inc. shareholders approved Ratification of RBSM LLP as independent registered public accounting firm at the 2023-08-09 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-08-09
Exact text from the filing
Proposal 4 – The Company’s stockholders ratified the appointment of RBSM LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain 2,794,638 126,032 63,296
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.